Cover Image
市場調查報告書

前列腺癌:關鍵意見領袖 (KOL) 的考察 - 最新趨勢簡報

Prostate Cancer: Update Bulletin [Feb 2016]

出版商 FirstWord 商品編碼 353279
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
前列腺癌:關鍵意見領袖 (KOL) 的考察 - 最新趨勢簡報 Prostate Cancer: Update Bulletin [Feb 2016]
出版日期: 2016年02月01日 內容資訊: 英文
簡介

本最新趨勢簡報,調查前列腺癌的治療藥的開發相關最新的事件和關鍵意見領袖 (KOL) 對其見解的彙整。

調查內容範例

  • custirsen (OGX-011; OncoGenex/Teva) 的第三階段親和性實驗中間分析的表現不佳,將成為閹割抗性前列腺癌 (mCRPC) 治療藥的終止符嗎?
  • TOPARP實驗有BRCA1/2及ATM遺傳基因變異的mCRPC的Lynparza (olaparib; AstraZeneca) 的作用有保證,不過,更廣泛的前列腺癌患者的適應可能性為何?
  • 對於英國NICE建議,化療實施前的mCRPC患者的治療非Zytiga (abiraterone acetate; Johnson & Johnson) 而應該使用Xtandi (enzalutamide; Astellas/Medivation) ,KOL的見解為何?
目錄

Gain new KOL insights on the latest events with the potential to shape the targeted treatment of Prostate Cancer (PC). Topics covered include opinions about the role of custirsen (OGX-011; OncoGenex/Teva) in combination with Jevtana (cabazitaxel; Sanofi) as a second-line treatment for metastatic castrate-resistant PC (mCRPC), and the development of Lynparza (olaparib; AstraZeneca) as a treatment for BRCA1/2 or ATM gene mutated mCRPC in patients who have received prior taxane-based chemotherapy and Zytiga (abiraterone acetate; Johnson & Johnson), or Xtandi (enzalutamide; Astellas/Medivation). The UK's National Institute for Health and Clinical Excellence's (NICE) recommendations concerning the use of Xtandi and Zytiga for treating mCRPC in a pre-chemotherapy setting are also discussed.

Key Questions Answered in this Update Bulletin:

  • Do the lacklustre results from the interim analysis of the Phase III AFFINITY trial spell the end for custirsen as a mCRPC therapy?
  • While the TOPARP study confirms Lynparza's activity in BRCA1/2 and ATM gene mutated mCRPC, how likely is it that the agent will be utilised in a wider prostate cancer patient population?
  • How do KOLs view the recommendations published by the UK's National Institute for Health and Clinical Excellence (NICE) that Xtandi, but not Zytiga, should be used to treat patients with mCRPC in the pre-chemotherapy setting?

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.

Back to Top